Osteomyelitis Global Market Report 2025

The osteomyelitis market size has grown strongly in recent years. It will grow from $1.02 billion in 2024 to $1.11 billion in 2025 at a compound annual growth rate (CAGR) of 9.1%. The market’s historical expansion can be attributed to advancements in bone grafting and regenerative medicine, increased healthcare spending, a growing elderly population, enhanced diagnostic capabilities, and a surge in intravenous (IV) drug usage.

The osteomyelitis market size is expected to see strong growth in the next few years. It will grow to $1.56 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. This anticipated growth is driven by a higher occurrence of diabetes, the rising burden of chronic illnesses, the spread of antibiotic resistance, increased adoption of biomarker-based testing, and heightened interest in agents that disrupt biofilms. Key trends during this period include the adoption of cutting-edge diagnostic methods, the use of artificial intelligence (AI) and digital tools, improvements in both treatment and surgical methods, the integration of AI-powered radiology tools, and the smart incorporation of technology into therapeutic approaches.

The increasing prevalence of chronic conditions is anticipated to drive the growth of the osteomyelitis market. Chronic conditions are long-term illnesses that often require ongoing treatment and management. This rise is largely attributed to the aging global population, as aging tends to weaken the immune system and increase vulnerability to persistent illnesses and infections. These chronic conditions elevate the risk of osteomyelitis by compromising immune defenses and blood circulation, especially in individuals with diabetes and vascular diseases. Such conditions foster an environment where infections can become chronic, heightening the chance of bone infection and complicating the recovery process. For example, in August 2023, a survey by the Institute for Health Metrics and Evaluation reported that 15% of people aged 30 and above had osteoarthritis in 2023, with projections estimating nearly 1 billion affected individuals by 2050. As a result, the increasing incidence of chronic conditions is contributing to the expansion of the osteomyelitis market.

Key players in the osteomyelitis market are introducing innovative treatments, such as premixed intravenous (IV) solutions, to address antibiotic resistance and enhance patient care. Premixed IV solutions are ready-to-administer sterile liquids containing specific medications or electrolytes, intended to increase safety and reduce preparation time in clinical settings. For instance, in September 2024, Hikma Pharmaceuticals Plc, a pharmaceutical company based in the UK, introduced a clindamycin injection formulated with 5% dextrose. This drug treats serious infections caused by susceptible anaerobic and gram-positive bacteria, including bone and joint infections such as acute hematogenous osteomyelitis. It offers a convenient IV treatment option, particularly beneficial for patients with penicillin allergies or when penicillin is unsuitable.

In March 2024, BiomX Inc., a biotechnology firm based in Israel, acquired Adaptive Phage Therapeutics Inc. for an undisclosed sum. This acquisition aims to establish BiomX as a leading phage therapy developer with a robust pipeline focused on Phase 2 assets for treating chronic pulmonary infections in cystic fibrosis and diabetic foot osteomyelitis. Adaptive Phage Therapeutics Inc., headquartered in the United States, is engaged in advancing phage therapy solutions specifically for osteomyelitis, including infections associated with diabetic foot ulcers.

Major players in the osteomyelitis market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Sanofi S.A., Abbott Laboratories, Novartis AG, GSK plc, Eli Lilly and Company, Siemens Healthineers, Otsuka Pharmaceutical Co. Ltd, Fresenius Kabi AG, Sumitomo Pharma Company Limited, Hikma Pharmaceuticals PLC, Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Wockhardt Hospitals, Basilea Pharmaceutica Ltd., Paratek Pharmaceuticals Inc., Debiopharm International SA, Accord Healthcare Limited, Melinta Therapeutics LLC, Cempra Inc., MicuRx Pharmaceuticals Inc., and Durata Therapeutics Inc.

North America was the largest region in the osteomyelitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in osteomyelitis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the osteomyelitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Osteomyelitis is a bone infection and inflammation that generally arises due to bacteria or fungi spreading through the bloodstream or from adjacent tissues. This condition can lead to bone damage and reduced blood circulation. Common symptoms include bone pain, fever, swelling, and in some cases, drainage of pus.

There are several primary types of osteomyelitis, including medullary osteomyelitis, superficial osteomyelitis, and others. Medullary osteomyelitis occurs when the infection is concentrated in the bone marrow cavity, typically stemming from hematogenous sources, with Staphylococcus aureus being the most frequent cause. Treatment options include a range of drug classes such as antibiotics, antifungals, non-steroidal anti-inflammatory drugs (NSAIDs), and others, which are administered either orally or through parenteral routes. These treatments are made available through hospital pharmacies, online pharmacies, and retail pharmacies, serving end-users such as hospitals and clinics, research institutions, diagnostic laboratories, and diagnostic centers. This organized framework ensures effective treatment delivery and availability for patients affected by osteomyelitis.

The osteomyelitis market research report is one of a series of new reports that provides osteomyelitis market statistics, including the osteomyelitis industry's global market size, regional shares, competitors with the osteomyelitis market share, detailed osteomyelitis market segments, market trends and opportunities, and any further data you may need to thrive in the osteomyelitis market. This osteomyelitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The osteomyelitis market consists of revenues earned by entities by providing services such as diagnostic imaging services, surgical debridement, infection control, antimicrobial therapy, hospitalization, post-operative rehabilitation, and long-term care management. The market value includes the value of related goods sold by the service provider or included within the service offering. The osteomyelitis market also includes sales of antibiotic-loaded bone cement, bone graft materials, orthopedic implants, wound care products, diagnostic kits, and surgical instruments. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.